Literature DB >> 30846260

Multiple vertebral fractures following discontinuation of denosumab treatment: Ten clinical cases report.

Elisa Fernández Fernández1, Diego Benavent Núñez2, Gema Bonilla Hernán2, Irene Monjo Henry2, Sara García Carazo2, Miguel Bernad Pineda2, Alejandro Balsa Criado2, Pilar Aguado Acín2.   

Abstract

OBJECTIVES: Analyse clinical and bone metabolism features in a case series of patients with multiple vertebral fractures after discontinuation of denosumab (DMab).
METHODS: An observational descriptive study analysing data from ten patients with multiple vertebral fractures after DMab discontinuation that were admitted to our rheumatology department between 2015 and 2018.
RESULTS: There were a total of 49 spontaneous fractures after an average of 6 DMab doses and 10.9 months from discontinuation. Ninety percent had already received treatment other than DMab 7 of 10 oral bisphosphonates. After discontinuation, CTX and P1NP remained elevated and mean T-score for femoral neck and lumbar spine was lower than before treatment. The most affected vertebrae were L3, L5, D6, D7, D9 and D11.
CONCLUSION: This report of ten new cases suffering multiple vertebral fractures early after discontinuation of DMab highlights the emerging concern on the subject in the scientific community and the need to clarify its pathogenic mechanism, and to support by solid evidence the new recommendations on its management.
Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Denosumab; Denosumab discontinuation; Efecto rebote; Fracturas vertebrales múltiples; Multiple vertebral fractures; Osteoporosis; Rebound effect; Suspensión denosumab

Mesh:

Substances:

Year:  2019        PMID: 30846260     DOI: 10.1016/j.reuma.2018.11.002

Source DB:  PubMed          Journal:  Reumatol Clin (Engl Ed)        ISSN: 2173-5743


  1 in total

1.  Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.

Authors:  Ruxu You; Jinyu Liu; Lei Ke; Min Wan; Yu Zhang; Guangyi Yu; Takahiro Mori
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.